Showing 1 - 10 of 572
Persistent link: https://www.econbiz.de/10010413143
Persistent link: https://www.econbiz.de/10011740630
Who gains from more information on the quality of pharmaceutical drugs? Are there incentives for voluntary post-approval clinical trials among pharmaceutical companies? Contrary to popular belief, this paper shows that it is not in the consumer interest that clinical evidence establishing the...
Persistent link: https://www.econbiz.de/10010281440
Persistent link: https://www.econbiz.de/10011313193
An urn contains balls of d = 2 colors. At each time n = 1, a ball is drawn and then replaced together with a random number of balls of the same color. Let An =diag (An,1, . . . ,An,d) be the n-th reinforce matrix. Assuming EAn,j = EAn,1 for all n and j, a few CLT s are available for such urns....
Persistent link: https://www.econbiz.de/10010343908
Persistent link: https://www.econbiz.de/10012631361
Persistent link: https://www.econbiz.de/10010207164
Persistent link: https://www.econbiz.de/10012299936
Randomised controlled or clinical trials (RCTs) are generally viewed as the most reliable method to draw causal inference as to the effects of a treatment, as they should guarantee that the individuals being compared differ only in terms of their exposure to the treatment of interest. This...
Persistent link: https://www.econbiz.de/10011580011
Persistent link: https://www.econbiz.de/10012062948